SCHEMBL3562374

SCHEMBL3562374

O=Cc1ccc(OCCCCOc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.64
ALDH1A1 P00352 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
LMNA P02545 1/20 0.61
MAPT P10636 1/20 0.61
HPGD P15428 1/20 0.61
KDM4E B2RXH2 1/20 0.57
PPARA Q07869 1/20 0.56
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
DRD2 P14416 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8392921 0.94 ALDH1A1 (0.58) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8551794 0.92 ALDH1A1 (0.69) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3113016 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8315263 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3696420 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8373486 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8549614 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8374769 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8373505 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8205008 0.90 ALDH1A1 (0.67) KCNA3ALDH1A1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP disclosed
US-7728023-B2 Indole compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080188532-A1 Indole Compound and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-07 US disclosed
EP-1852420-A1 INDOLE COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188532-A1 Indole Compound and Use Thereof CYSLTR1, LTC4S, IDO1 KCNA3 2925/4885ALDH1A1 1805/4885SMN1; SMN2 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.